About Theralase Technologies (CVE:TLT)
Theralase Technologies Inc. designs, develops, manufactures, and markets super-pulsed cold laser technology for a range of human, companion animal, and equine applications. The company operates in two divisions, Therapeutic Laser Technology and Photo Dynamic Therapy. It engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of nerve, muscle, tendon, ligament, joint, and wound conditions through the elimination of pain, reduction of inflammation, and acceleration of tissue healing. The company is also involved in the research, development, and commercialization of the patented and patent pending TLC-3000 medical laser and photo dynamic compound anti-cancer technology through preclinical research, clinical trials, and technology development to destroy cancers for oncological applications, as well as to destroy bacteria for human, animal, and sterilization applications. In addition, it operates a full service medical rehabilitation clinic in Toronto, Ontario for training and education of health-care practitioners. The company sells its products to licensed healthcare practitioners in Canada, the United States, and internationally. Theralase Technologies Inc. has strategic partnerships with University Health Network, Ontario Centers of Excellence for Photonics, National Research Council of Canada, Virginia Tech, The Scripps Research Institute, Mayo Clinic, University of Buffalo, and JSS Medical Research, as well as clinical research agreements with Princess Margaret Cancer Centre and University Health Network. The company was founded in 1995 and is based in Toronto, Canada.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Trailing P/E Ratio-4.5
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-175.04%
Return on Assets-153.91%
Theralase Technologies (CVE:TLT) Frequently Asked Questions
What is Theralase Technologies' stock symbol?
Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."
How were Theralase Technologies' earnings last quarter?
Theralase Technologies Inc. (CVE:TLT) released its earnings results on Wednesday, November, 29th. The company reported ($0.01) EPS for the quarter. Theralase Technologies had a negative net margin of 346.71% and a negative return on equity of 175.04%. View Theralase Technologies' Earnings History.
When will Theralase Technologies make its next earnings announcement?
Who are some of Theralase Technologies' key competitors?
Some companies that are related to Theralase Technologies include Cancer Genetics (CGIX), Cardiome Pharma (CRME), Neovasc Inc (US) (NVCN), Digirad (DRAD), SCYNEXIS (SCYX), VIVUS (VVUS), ReNeuron Group (RENE), CytRx (CYTR), Xenon Pharmaceuticals (XENE), Alphatec (ATEC), pSivida (PSDV), Electromed (ELMD), OptiBiotix Health (OPTI), ANGLE (AGL), Ocera Therapeutics (OCRX), Capricor Therapeutics (CAPR), Immutep (IMMP) and Reshape Lifesciences (RSLS).
Who are Theralase Technologies' key executives?
Theralase Technologies' management team includes the folowing people:
- Roger Dumoulin-White, President, Chief Executive Officer, Director
- Kristina Hachey, Chief Financial Officer
- Michael Borovec, Director of Investor Relations
- Matthew Perraton, Director
- Guy John Anderson, Independent Director (Age 1)
- Randall Bruder, Independent Director
How do I buy Theralase Technologies stock?
Shares of Theralase Technologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theralase Technologies' stock price today?
One share of Theralase Technologies stock can currently be purchased for approximately C$0.23.
How big of a company is Theralase Technologies?
Theralase Technologies has a market capitalization of C$27.83 million.
How can I contact Theralase Technologies?
Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273.
MarketBeat Community Rating for Theralase Technologies (TLT)MarketBeat's community ratings are surveys of what our community members think about Theralase Technologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Theralase Technologies (CVE:TLT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Theralase Technologies (CVE:TLT) Earnings History and Estimates Chart
Theralase Technologies (CVE TLT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/7/2018|| || || || || || || || |
Theralase Technologies (CVE:TLT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Theralase Technologies (CVE:TLT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Theralase Technologies (CVE TLT)
No insider trades for this company have been tracked by MarketBeat.com
Theralase Technologies (CVE TLT) News Headlines
Theralase Technologies (CVE:TLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Theralase Technologies (CVE TLT) Stock Chart for Tuesday, January, 16, 2018